Jose A Seoane
Junior Group Leader
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (9)
Purpose: Gene fusions are molecular rearrangements with oncogenic potential. However, their role in disease progression and therapy resistance remains largely unexplored, particularly in breast cancer. Experimental Design: In this study, we utilized multiomics data from the AURORA program to characterize gene fusions in metastatic breast cancer. We analyzed RNA sequencing data from 325 primary tumors and 350 metastatic lesions across 476 patients to develop a high-confidence catalog of gene fusions. Results: In a subset of 398 matched samples from 199 patients, we observed a higher burden of gene fusions in metastatic tumors compared with their corresponding primary tumors. Metastatic-specific (acquired) gene fusions were characterized by few recurrent rearrangements and were generally absent in patients with de novo metastatic disease. We observed a colocalization of gene fusions with subtype-specific copy-number gains. Various scores indicative of genomic instability were found to be associated with the gene fusion burden. Fusions involving genes located within the same topologically associating domain (TAD) were common in HER2-positive tumors and frequently acquired in metastatic triple-negative breast cancer. The presence of gene fusions, particularly those that were acquired or involved in genes within the same TAD, was associated with poor prognosis in estrogen receptor–positive/HER2-negative tumors. Patients with acquired ESR1 fusions exhibited a more aggressive disease course, characterized by shorter treatment response and poorer clinical outcomes. Conclusions: The AURORA gene fusion catalog may serve as a valuable resource for identifying targetable genetic alterations, thereby supporting the development of more effective therapeutic strategies for breast cancer.
Year:
2026
Year:
2025
Year:
2025
Year:
2025
Colon cancer is the second most common cause of cancer death worldwide. Despite advances in the development of new molecular strategies for stratifying patients with colon cancer, many of these patients do not respond adequately to the standard of care. While previous studies have focused on the development of prognostic gene expression signatures, the exploration of predictive signatures to inform treatment decisions remains incomplete. In this study, we leveraged public gene expression datasets to design and experimentally validate a 37-gene expression signature for prognosis in colon cancer patients. We obtained a C-index of 0.732 (0.610-0.853) in four independent studies. Specifically, we discovered that the signature is associated with the mitotic phase of the cell cycle. Furthermore, the signature identified a population of colon cancer patients sensitive to tubulin inhibitor drugs. In particular, we validated in vitro and in vivo the efficacy of paclitaxel, a commonly used tubulin inhibitor in breast cancer treatment, in patient-derived preclinical models. These results highlight the importance of incorporating gene expression signatures to identify new therapeutic options for colon cancer treatment. Furthermore, the identification of alternative treatment options with potentially improved efficacy holds promise for the development of new clinical trials, and reshapes the biomarker-based treatment strategy for second line and refractory colon cancer patients.
Year:
2025
Rosano, Sofyali, Dhiman, and colleagues show that epigenetic-related changes occur in endocrine therapy (ET)-induced dormancy in estrogen receptor positive (ER+) breast cancer, as well as in its reawakening. Targeting these epigenetic changes blocks the entrance to dormancy and reduces the persister cancer cell population, enhancing the cytotoxic effects of ET in vitro. See related article by Rosano et al., p. 866 (9).
Year:
2024
The incidence of colorectal cancer (CRC) is rapidly rising in individuals younger than 50, particularly in high-income countries. This rise parallels shifts in lifestyle and environmental factors, collectively termed the exposome; however, whether these are causally linked to the development of early-onset CRC (EOCRC) has not been investigated. Due to limited exposome data in most cancer cohorts, we constructed weighted methylation risk scores (MRS) as proxies for exposome exposure to pinpoint specific risk factors associated with EOCRC. Our analysis confirms previously identified risk factors, such as educational attainment, diet, and smoking habits. Moreover, we identified the exposure to the herbicide picloram as a novel risk factor (Padj. = 0.00049), a result we replicated in a meta-analysis comprising six CRC cohorts (P = 0.021), comparing EOCRC cases with patients diagnosed aged ≥70. Subsequently, we employed population-based data from 81 U.S. counties over 20 years and validated the association between picloram usage and EOCRC incidence (P = 2.87×10 -3 ). These findings highlight the critical role of the exposome in EOCRC risk, underscoring the urgency for targeted personal and policy-level interventions.
Year:
2024
Year:
2023
Year:
2023
Collaborators (11)
Christos Sotiriou
Université libre de Bruxelles
Matteo Benelli
Head of Bioinformatics Unit
Azienda Usl Toscana Centro
Miguel F. Segura
Head of the Laboratory of Neural Tumors
Vall d'Hebron Institut de Recerca
Andrea Vingiani
Fondazione IRCCS Istituto Nazionale dei Tumori
Carlos Fernandez-Lozano
Associate professor (tenure track)
Universidade da Coruña
Ana Vivancos
Principal Investigator
Vall d'Hebron Institute of Oncology
Josep Tabernero
Associate Professor Faculty of Medicine
Universitat de Vic - Universitat Central de Catalunya
Giuseppe Curigliano
European Institute of Oncology
Elisa Agostinetto
Institut Jules Bordet
Danai Fimereli
Université libre de Bruxelles (ULB)
Gabriele Zoppoli
University of Genoa
Make your next move.
Prepare your application
Review drafts before you send them.